TY - JOUR
T1 - Survival after pulmonary metastasectomy in soft tissue sarcoma
T2 - Prognostic factors in 214 patients
AU - Choong, Peter F.M.
AU - Pritchard, Douglas J.
AU - Rock, Michael G.
AU - Sim, Franklin H.
AU - Frassica, Frank J.
PY - 1995/1/1
Y1 - 1995/1/1
N2 - This retrospective study examines prognostic factors for post-metastasectomy survival in soft tissue sarcoma patients. Between 1976 and 1992, 274 consecutive patients (median age 49 [7-96] years) with pulmonary metastatic soft tissue sarcoma of the extremity or trunk wall (31 at presentation) were managed at the Mayo Clinic. 21 4 underwent pulmonary metastasectomy and 163 of these also received adjuvant chemotherapy. There were 195 local excisions, 14 lobectomies, and 5 pneumonectomies. 90 patients had solitary metastases, 184 patients had 2 or more metastases. 31 YO of patients had MFH tumors and 88% of all tumors were high grade. Median follow-up for survivors was 8 (2-21) years. 5-year overall survival after metastasectomy was =40% (cf. 20% for non-metastasectomy). Age > 50, MFH tumors, ≥ 2 metastases, metastasis size > 2 cm, metastasis-free period ≤18 months, and the use of adjuvant chemotherapy were univariately unfavorable factors. Size of metastasis > 2 cm, number of metastases ≥2, and metastasis-free interval ≤ 18 months were independently unfavorable for survival. In a prognostic system, patients with 0 risk factors had a 60% 5-year survival, those with 1, 2, or 3 of these factors had 30% 20% and 0% survival, respectively.
AB - This retrospective study examines prognostic factors for post-metastasectomy survival in soft tissue sarcoma patients. Between 1976 and 1992, 274 consecutive patients (median age 49 [7-96] years) with pulmonary metastatic soft tissue sarcoma of the extremity or trunk wall (31 at presentation) were managed at the Mayo Clinic. 21 4 underwent pulmonary metastasectomy and 163 of these also received adjuvant chemotherapy. There were 195 local excisions, 14 lobectomies, and 5 pneumonectomies. 90 patients had solitary metastases, 184 patients had 2 or more metastases. 31 YO of patients had MFH tumors and 88% of all tumors were high grade. Median follow-up for survivors was 8 (2-21) years. 5-year overall survival after metastasectomy was =40% (cf. 20% for non-metastasectomy). Age > 50, MFH tumors, ≥ 2 metastases, metastasis size > 2 cm, metastasis-free period ≤18 months, and the use of adjuvant chemotherapy were univariately unfavorable factors. Size of metastasis > 2 cm, number of metastases ≥2, and metastasis-free interval ≤ 18 months were independently unfavorable for survival. In a prognostic system, patients with 0 risk factors had a 60% 5-year survival, those with 1, 2, or 3 of these factors had 30% 20% and 0% survival, respectively.
UR - http://www.scopus.com/inward/record.url?scp=0029587269&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029587269&partnerID=8YFLogxK
U2 - 10.3109/17453679509002316
DO - 10.3109/17453679509002316
M3 - Article
C2 - 8553829
AN - SCOPUS:0029587269
SN - 1745-3674
VL - 66
SP - 561
EP - 568
JO - Acta Orthopaedica
JF - Acta Orthopaedica
IS - 6
ER -